145 related articles for article (PubMed ID: 22480860)
1. [The industrial future small batches].
Conduzorgues JP
Presse Med; 2012 May; 41 Suppl 1():S55-6. PubMed ID: 22480860
[No Abstract] [Full Text] [Related]
2. Toward biosimilar monoclonal antibodies.
Schneider CK; Kalinke U
Nat Biotechnol; 2008 Sep; 26(9):985-90. PubMed ID: 18779806
[No Abstract] [Full Text] [Related]
3. Embedding sustainable practices into pharmaceutical R&D: what are the challenges?
Sneddon H
Future Med Chem; 2014; 6(12):1373-6. PubMed ID: 25329193
[No Abstract] [Full Text] [Related]
4. Vertical disintegration: a strategy for pharmaceutical businesses in 2009?
Dixon J; Lawton G; Machin P
Nat Rev Drug Discov; 2009 Jun; 8(6):435. PubMed ID: 19483701
[No Abstract] [Full Text] [Related]
5. Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes.
Finkelstein PE
AMA J Ethics; 2015 Dec; 17(12):1142-6. PubMed ID: 26698587
[No Abstract] [Full Text] [Related]
6. Fairer way to distribute last-ditch drugs gets real-world trial.
Reardon S
Nature; 2016 Jun; 534(7606):160-1. PubMed ID: 27279187
[No Abstract] [Full Text] [Related]
7. Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics.
Fitzgerald GA
Nat Rev Drug Discov; 2005 Oct; 4(10):815-8. PubMed ID: 16224453
[TBL] [Abstract][Full Text] [Related]
8. Ask the experts: the challenges and benefits of flow chemistry to optimize drug development.
Anderson N; Gernaey KV; Jamison TF; Kircher M; Wiles C; Leadbeater NE; Sandford G; Richardson P
Future Med Chem; 2012 Sep; 4(14):1779-89. PubMed ID: 23043475
[TBL] [Abstract][Full Text] [Related]
9. Where will we get the next generation of medicinal chemists?
Allen D
Drug Discov Today; 2016 May; 21(5):704-6. PubMed ID: 27131748
[No Abstract] [Full Text] [Related]
10. High throughput screening: early successes indicate a promising future.
Fox S; Wang H; Sopchak L; Khoury R
J Biomol Screen; 2001 Jun; 6(3):137-40. PubMed ID: 11689109
[No Abstract] [Full Text] [Related]
11. Europe's sweeping chemical law puts medicines in peril.
Keim B
Nat Med; 2007 Jan; 13(1):4. PubMed ID: 17297677
[No Abstract] [Full Text] [Related]
12. Europe caught in innovation quagmire.
Mitchell P
Nat Biotechnol; 2005 Sep; 23(9):1029. PubMed ID: 16151378
[No Abstract] [Full Text] [Related]
13. Chemistry: Develop ionic liquid drugs.
Shamshina JL; Kelley SP; Gurau G; Rogers RD
Nature; 2015 Dec; 528(7581):188-9. PubMed ID: 26659168
[No Abstract] [Full Text] [Related]
14. Prologue: chirality in the pharmaceutical industry.
Caldwell J; Berova N; McConnell O
Chirality; 2007 Sep; 19(9):657. PubMed ID: 17657706
[No Abstract] [Full Text] [Related]
15. Combinatorial chemistry at the crossroads.
Whitehead RS
Nat Biotechnol; 1998 Jan; 16(1):2-3. PubMed ID: 9447574
[No Abstract] [Full Text] [Related]
16. The strange allure of state "right-to-try" laws.
Zettler PJ; Greely HT
JAMA Intern Med; 2014 Dec; 174(12):1885-6. PubMed ID: 25264589
[No Abstract] [Full Text] [Related]
17. Drug life-cycle technologies.
Fleming E; Ma P
Nat Rev Drug Discov; 2002 Oct; 1(10):751-2. PubMed ID: 12360253
[No Abstract] [Full Text] [Related]
18. The role of the chemical biology core facility at EMBL: a vision for a European roadmap.
Lewis JD
ACS Chem Biol; 2007 Jan; 2(1):21-3. PubMed ID: 17243779
[No Abstract] [Full Text] [Related]
19. Rob Ashley of AmpliMed discusses the discovery and development of Imexon. Interview by Steve Carney.
Ashley RA
Drug Discov Today; 2005 Oct; 10(20):1339-42. PubMed ID: 16253868
[No Abstract] [Full Text] [Related]
20. Upping the ante on antibodies.
Baker M
Nat Biotechnol; 2005 Sep; 23(9):1065-72. PubMed ID: 16151393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
